dc.contributor
Institut Català de la Salut
dc.contributor
[Swain SM] Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, Washington, USA. [Macharia H] F. Hoffmann-La Roche Ltd., Basel, Switzerland. [Cortes J] Quirónsalud Group, IOB Institute of Oncology, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Dang C] Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, USA. [Gianni L] Fondazione Michelangelo, Milano, Italy. [Hurvitz SA] David Geffen School of Medicine, University of California, Los Angeles, USA
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Swain, Sandra
dc.contributor.author
Macharia, Harrison
dc.contributor.author
Cortés Castan, Javier
dc.contributor.author
Hurvitz, Sara
dc.contributor.author
Gianni, Luca
dc.contributor.author
Dang, Chau
dc.date.accessioned
2025-10-25T05:39:03Z
dc.date.available
2025-10-25T05:39:03Z
dc.date.issued
2022-11-28T11:23:56Z
dc.date.issued
2022-11-28T11:23:56Z
dc.date.issued
2022-10-15
dc.identifier
Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz SA, et al. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. Cancers. 2022 Oct 15;14(20):5051.
dc.identifier
https://hdl.handle.net/11351/8541
dc.identifier
10.3390/cancers14205051
dc.identifier
000872655600001
dc.identifier.uri
http://hdl.handle.net/11351/8541
dc.description.abstract
Early breast cancer; Event-free survival; Pathologic complete response
dc.description.abstract
Cáncer de mama temprano; Supervivencia libre de eventos; Respuesta patológica completa
dc.description.abstract
Càncer de mama precoç; Supervivència lliure d'esdeveniments; Resposta patològica completa
dc.description.abstract
The standard-of-care for patients with pathological complete response (pCR) after neoadjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. Our objective was to evaluate risk of recurrence or death in these patients and determine if outcomes differed by the HER2-targeted regimen received in each setting. We analyzed patient-level data from five randomized trials evaluating trastuzumab, pertuzumab, or both as part of systemic neoadjuvant and adjuvant therapy for HER2-positive early breast cancer, and assessed event-free survival (EFS) in 1763 patients. Patients with pCR had decreased risk of an EFS event versus those with residual disease (unadjusted hazard ratio [HR] = 0.35; 95% confidence interval [CI]: 0.27–0.46). Regardless of pCR status, after adjusting for baseline factors, reduction in EFS event risk was greater in patients administered pertuzumab/trastuzumab in both settings versus those administered only trastuzumab in both settings (HR = 0.36; 95% CI: 0.26–0.49), or pertuzumab/trastuzumab in the neoadjuvant setting and only trastuzumab in the adjuvant setting (HR = 0.67; 95% CI: 0.47–0.96). Patients with pCR had longer EFS than those with residual disease. Patients treated with pertuzumab/trastuzumab in both the neoadjuvant and adjuvant settings had the lowest risk of breast cancer recurrence.
dc.description.abstract
The analysis was funded by F. Hoffmann-La Roche, Ltd.
dc.format
application/pdf
dc.relation
Cancers;14(20)
dc.relation
https://doi.org/10.3390/cancers14205051
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Mama - Càncer - Tractament
dc.subject
Quimioteràpia combinada
dc.subject
Anàlisi de supervivència (Biometria)
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Disease-Free Survival
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia sin enfermedad
dc.title
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
